The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial.  McAnulty C, Bastien G…

"Trust and suspicion" Client and provider perspectives on the acceptability of medication for opioid use disorder among people who inject drugs in Kampala, Uganda.  Mudiope P, Nanyeenya N, Simon O, Twimukye A, Simon K, Brian MB, Nangendo J, Al…

Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.  Khatri UG, Lopez C, Yen Y, Ling EJ, Richardson LD, Ngai KM.  JAMA Netw Open. 2025;8(6):e2518493. doi…

Ongoing Gaps in Buprenorphine Treatment—Urgency and Opportunity.  Wakeman SE.  JAMA Netw Open. 2025;8(6):e2518500. doi:10.1001/jamanetworkopen.2025.18500 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835699

Retention in Opioid Agonist Therapy Among First Nations People.  Holton A, Hamzat B, McCormack D, et al.  JAMA Netw Open. 2025;8(6):e2518452. doi:10.1001/jamanetworkopen.2025.18452 https://jamanetwork.com/journals/jamanetworkopen/fullar…

Emergency Department-Based Medication for Opioid Use Disorder: A 5-Year Experience.  Seaberg DC, McKinnon J, Haselton L, Reuter Q, Kolb J, Vellanki S, Morah JC, Oskvarek J, Jouriles N.  J Am Coll Emerg Physicians Open. 2025 Jun 3;6(4):10…